Sale!

t1119 q23p13.3 MLL-ENL PCR Qualitative Test

1,000 د.إ

-23%

The T1119 q23p13.3 MLL-ENL PCR Qualitative Test is a specialized diagnostic assay performed at DNA Labs UAE, designed to detect specific chromosomal translocations involving the MLL (Mixed Lineage Leukemia) gene on chromosome 11 and the ENL (Eleven-Nineteen Leukemia) gene on chromosome 19. This translocation is often associated with various types of leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), making this test a crucial tool for accurate diagnosis and treatment planning.

Utilizing the Polymerase Chain Reaction (PCR) technique, this qualitative test amplifies DNA sequences to identify the presence of the MLL-ENL fusion gene, providing clinicians with vital information on the genetic basis of the patient’s leukemia. The test’s qualitative nature means it determines the presence or absence of the translocation, rather than quantifying it.

Performed in the state-of-the-art facilities of DNA Labs UAE, the T1119 q23p13.3 MLL-ENL PCR Qualitative Test is priced at 1000 AED. This cost reflects the sophisticated technology and expertise required to conduct such precise genetic testing, contributing to the overall goal of delivering personalized medicine and improving patient outcomes in the United Arab Emirates.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

t1119 q23p13.3 MLL-ENL PCR QUALITATIVE Test

Test Name: t1119 q23p13.3 MLL-ENL PCR QUALITATIVE Test

Components: Price: 1000.0 AED

Sample Condition: 3mL(2mLmin.) wholeblood/Bone marrowin1LavenderTop(EDTA) tube.Shiprefrigerated.DONOT FREEZE. Clinical history is mandatory.

Report Delivery: SampleMon / Thu by 11am; Report Wed /Sat

Method: Real Time PCR

Test type: Leukemia

Doctor: Oncologist

Test Department: MOLECULAR DIAGNOSTICS

Pre Test Information: Clinical history is mandatory.

Test Details:

The t(11;19)(q23;p13.3) translocation, also known as MLL-ENL fusion, is a genetic abnormality commonly found in acute myeloid leukemia (AML). This translocation results in the fusion of the MLL (Mixed-Lineage Leukemia) gene on chromosome 11 with the ENL (Eleven-Nineteen Leukemia) gene on chromosome 19.

The PCR (Polymerase Chain Reaction) qualitative test is a molecular diagnostic technique used to detect the presence or absence of specific genetic alterations, such as the MLL-ENL fusion. It involves amplifying and analyzing the DNA of a patient’s cells to identify the fusion gene.

The qualitative PCR test for t(11;19)(q23;p13.3) can help confirm the presence of this translocation in AML patients. This information is important for accurate diagnosis, prognosis, and treatment planning, as certain targeted therapies may be more effective against leukemia cells with this specific genetic alteration.

Test Name t1119 q23p13.3 MLL-ENL PCR QUALITATIVE Test
Components
Price 1000.0 AED
Sample Condition 3mL(2mLmin.) wholeblood\/Bone marrowin1LavenderTop(EDTA) tube.Shiprefrigerated.DONOT FREEZE. Clinical history is mandatory.
Report Delivery SampleMon / Thu by 11am;Report Wed /Sat
Method Real Time PCR
Test type Leukemia
Doctor Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Clinical history is mandatory.
Test Details

The t(11;19)(q23;p13.3) translocation, also known as MLL-ENL fusion, is a genetic abnormality commonly found in acute myeloid leukemia (AML). This translocation results in the fusion of the MLL (Mixed-Lineage Leukemia) gene on chromosome 11 with the ENL (Eleven-Nineteen Leukemia) gene on chromosome 19.

The PCR (Polymerase Chain Reaction) qualitative test is a molecular diagnostic technique used to detect the presence or absence of specific genetic alterations, such as the MLL-ENL fusion. It involves amplifying and analyzing the DNA of a patient’s cells to identify the fusion gene.

The qualitative PCR test for t(11;19)(q23;p13.3) can help confirm the presence of this translocation in AML patients. This information is important for accurate diagnosis, prognosis, and treatment planning, as certain targeted therapies may be more effective against leukemia cells with this specific genetic alteration.